aTYR PHARMA INC Operating Cash Flow
aTYR PHARMA INC (ATYR) reported Operating Cash Flow of -$21.87 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-07.
Financial Statements › Cash Flow › Operating Activities
us-gaap:NetCashProvidedByUsedInOperatingActivities · last filed 2026-08-07
- aTYR PHARMA INC net cash provided by (used in) operating activities for the quarter ending 2026-06-30 was -$9.35M.
- aTYR PHARMA INC net cash provided by (used in) operating activities for the quarter ending 2026-03-31 was -$12.52M.
- aTYR PHARMA INC net cash provided by (used in) operating activities for the quarter ending 2025-12-31 was -$12.20M.
- aTYR PHARMA INC net cash provided by (used in) operating activities for the quarter ending 2025-09-30 was -$20.48M.
- aTYR PHARMA INC net cash provided by (used in) operating activities for fiscal 2025 was -$61.99M.
- aTYR PHARMA INC net cash provided by (used in) operating activities for fiscal 2024 was -$69.12M.
- aTYR PHARMA INC net cash provided by (used in) operating activities for fiscal 2023 was -$33.22M.
- aTYR PHARMA INC net cash provided by (used in) operating activities for fiscal 2022 was -$41.89M.
| Period end | Net Cash Provided by (Used in) Operating Activities 3 month | Net Cash Provided by (Used in) Operating Activities 6 month | Net Cash Provided by (Used in) Operating Activities 9 month | Net Cash Provided by (Used in) Operating Activities 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$9.35M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-07 | -$21.87M 10-Q · filed 2026-08-07 | -$34.06M derived: sum of 3 quarters · filed 2026-08-07 | -$54.54M derived: sum of 4 quarters · filed 2026-08-07 |
| 2026-03-31 | -$12.52M 10-Q · filed 2026-05-15 | -$24.71M derived: sum of 2 quarters · filed 2026-05-15 | -$45.19M derived: sum of 3 quarters · filed 2026-05-15 | -$59.08M derived: sum of 4 quarters · filed 2026-08-07 |
| 2025-12-31 | -$12.20M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | -$32.67M derived: sum of 2 quarters · filed 2026-03-05 | -$46.57M derived: sum of 3 quarters · filed 2026-08-07 | -$61.99M 10-K · filed 2026-03-05 |
| 2025-09-30 | -$20.48M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | -$34.37M derived: sum of 2 quarters · filed 2026-08-07 | -$49.79M 10-Q · filed 2025-11-06 | -$62.92M derived: sum of 4 quarters · filed 2026-08-07 |
| 2025-06-30 | -$13.89M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-07 | -$29.31M 10-Q · filed 2026-08-07 | -$42.45M derived: sum of 3 quarters · filed 2026-08-07 | -$55.60M derived: sum of 4 quarters · filed 2026-08-07 |
| 2025-03-31 | -$15.42M 10-Q · filed 2026-05-15 | -$28.55M derived: sum of 2 quarters · filed 2026-05-15 | -$41.71M derived: sum of 3 quarters · filed 2026-05-15 | -$62.16M derived: sum of 4 quarters · filed 2026-05-15 |
| 2024-12-31 | -$13.13M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | -$26.29M derived: sum of 2 quarters · filed 2026-03-05 | -$46.74M derived: sum of 3 quarters · filed 2026-03-05 | -$69.12M 10-K · filed 2026-03-05 |
| 2024-09-30 | -$13.16M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | -$33.61M derived: sum of 2 quarters · filed 2025-11-06 | -$55.99M 10-Q · filed 2025-11-06 | -$67.05M derived: sum of 4 quarters · filed 2026-03-05 |
| 2024-06-30 | -$20.45M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | -$42.83M 10-Q · filed 2025-08-07 | -$53.89M derived: sum of 3 quarters · filed 2026-03-05 | -$63.45M derived: sum of 4 quarters · filed 2026-03-05 |
| 2024-03-31 | -$22.38M 10-Q · filed 2025-05-07 | -$33.44M derived: sum of 2 quarters · filed 2026-03-05 | -$43.00M derived: sum of 3 quarters · filed 2026-03-05 | -$55.01M derived: sum of 4 quarters · filed 2026-03-05 |
| 2023-12-31 | -$11.06M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | -$20.62M derived: sum of 2 quarters · filed 2026-03-05 | -$32.63M derived: sum of 3 quarters · filed 2026-03-05 | -$33.22M 10-K · filed 2026-03-05 |
| 2023-09-30 | -$9.56M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | -$21.57M derived: sum of 2 quarters · filed 2024-11-07 | -$22.16M 10-Q · filed 2024-11-07 | -$32.53M derived: sum of 4 quarters · filed 2025-03-13 |
| 2023-06-30 | -$12.01M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-13 | -$12.60M 10-Q · filed 2024-08-13 | -$22.97M derived: sum of 3 quarters · filed 2025-03-13 | -$35.25M derived: sum of 4 quarters · filed 2025-03-13 |
| 2023-03-31 | -$590.00K 10-Q · filed 2024-05-02 | -$10.96M derived: sum of 2 quarters · filed 2025-03-13 | -$23.24M derived: sum of 3 quarters · filed 2025-03-13 | -$32.36M derived: sum of 4 quarters · filed 2025-03-13 |
| 2022-12-31 | -$10.37M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-13 | -$22.65M derived: sum of 2 quarters · filed 2025-03-13 | -$31.77M derived: sum of 3 quarters · filed 2025-03-13 | -$41.89M 10-K · filed 2025-03-13 |
| 2022-09-30 | -$12.28M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | -$21.40M derived: sum of 2 quarters · filed 2023-11-09 | -$31.52M 10-Q · filed 2023-11-09 | -$39.60M derived: sum of 4 quarters · filed 2024-03-14 |
| 2022-06-30 | -$9.12M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-09 | -$19.24M 10-Q · filed 2023-08-09 | -$27.32M derived: sum of 3 quarters · filed 2024-03-14 | -$38.79M derived: sum of 4 quarters · filed 2024-03-14 |
| 2022-03-31 | -$10.12M 10-Q · filed 2023-05-09 | -$18.20M derived: sum of 2 quarters · filed 2024-03-14 | -$29.68M derived: sum of 3 quarters · filed 2024-03-14 | -$37.37M derived: sum of 4 quarters · filed 2024-03-14 |
| 2021-12-31 | -$8.09M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-14 | -$19.56M derived: sum of 2 quarters · filed 2024-03-14 | -$27.25M derived: sum of 3 quarters · filed 2024-03-14 | -$33.08M 10-K · filed 2024-03-14 |
| 2021-09-30 | -$11.47M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | -$19.16M derived: sum of 2 quarters · filed 2022-11-14 | -$24.99M 10-Q · filed 2022-11-14 | -$30.39M derived: sum of 4 quarters · filed 2023-03-14 |
| 2021-06-30 | -$7.69M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-15 | -$13.52M 10-Q · filed 2022-08-15 | -$18.92M derived: sum of 3 quarters · filed 2023-03-14 | -$24.48M derived: sum of 4 quarters · filed 2023-03-14 |
| 2021-03-31 | -$5.83M 10-Q · filed 2022-05-10 | -$11.23M derived: sum of 2 quarters · filed 2023-03-14 | -$16.78M derived: sum of 3 quarters · filed 2023-03-14 | -$23.19M derived: sum of 4 quarters · filed 2023-03-14 |
| 2020-12-31 | -$5.40M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-14 | -$10.96M derived: sum of 2 quarters · filed 2023-03-14 | -$17.36M derived: sum of 3 quarters · filed 2023-03-14 | -$15.30M 10-K · filed 2023-03-14 |
| 2020-09-30 | -$5.55M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-12 | -$11.96M derived: sum of 2 quarters · filed 2021-11-12 | -$9.90M 10-Q · filed 2021-11-12 | -$14.82M derived: sum of 4 quarters · filed 2022-03-15 |
| 2020-06-30 | -$6.40M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-11 | -$4.34M 10-Q · filed 2021-08-11 | -$9.26M derived: sum of 3 quarters · filed 2022-03-15 | -$13.51M derived: sum of 4 quarters · filed 2022-03-15 |
| 2020-03-31 | $2.06M 10-Q · filed 2021-05-14 | -$2.86M derived: sum of 2 quarters · filed 2022-03-15 | -$7.11M derived: sum of 3 quarters · filed 2022-03-15 | -$11.93M derived: sum of 4 quarters · filed 2022-03-15 |
| 2019-12-31 | -$4.92M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-15 | -$9.17M derived: sum of 2 quarters · filed 2022-03-15 | -$13.99M derived: sum of 3 quarters · filed 2022-03-15 | -$20.01M 10-K · filed 2022-03-15 |
| 2019-09-30 | -$4.25M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-13 | -$9.07M derived: sum of 2 quarters · filed 2020-11-13 | -$15.10M 10-Q · filed 2020-11-13 | -$19.94M derived: sum of 4 quarters · filed 2021-03-24 |
| 2019-06-30 | -$4.82M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-13 | -$10.84M 10-Q · filed 2020-08-13 | -$15.68M derived: sum of 3 quarters · filed 2021-03-24 | -$22.14M derived: sum of 4 quarters · filed 2021-03-24 |
| 2019-03-31 | -$6.02M 10-Q · filed 2020-05-12 | -$10.86M derived: sum of 2 quarters · filed 2021-03-24 | -$17.32M derived: sum of 3 quarters · filed 2021-03-24 | -$26.51M derived: sum of 4 quarters · filed 2021-03-24 |
| 2018-12-31 | -$4.84M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-24 | -$11.30M derived: sum of 2 quarters · filed 2021-03-24 | -$20.49M derived: sum of 3 quarters · filed 2021-03-24 | -$31.06M 10-K · filed 2021-03-24 |
| 2018-09-30 | -$6.46M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-14 | -$15.65M derived: sum of 2 quarters · filed 2019-11-14 | -$26.22M 10-Q · filed 2019-11-14 | -$36.53M derived: sum of 4 quarters · filed 2020-03-26 |
| 2018-06-30 | -$9.19M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-14 | -$19.76M 10-Q · filed 2019-08-14 | -$30.07M derived: sum of 3 quarters · filed 2020-03-26 | -$38.96M derived: sum of 4 quarters · filed 2020-03-26 |
| 2018-03-31 | -$10.58M 10-Q · filed 2019-05-14 | -$20.88M derived: sum of 2 quarters · filed 2020-03-26 | -$29.78M derived: sum of 3 quarters · filed 2020-03-26 | |
| 2017-12-31 | -$10.31M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-26 | -$19.20M derived: sum of 2 quarters · filed 2020-03-26 | -$42.36M 10-K · filed 2020-03-26 | |
| 2017-09-30 | -$8.89M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-14 | -$32.06M 10-Q · filed 2018-11-14 | ||
| 2017-06-30 | -$23.16M 10-Q · filed 2018-08-14 | |||
| 2016-12-31 | -$52.86M 10-K · filed 2019-03-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Quince Therapeutics, Inc. (QNCX) | United States | $0.031B | |
| CEL SCI CORP (CVM) | United States | $0.030B | -0.81 |
| Scilex Holding Co (SCLX) | United States | $0.042B | -0.14 |
| Metagenomi Therapeutics, Inc. (MGX) | United States | $0.044B | -0.48 |
| Estrella Immunopharma, Inc. (ESLA) | United States | $0.020B | |
| LeonaBio, Inc. (LONA) | United States | $0.047B | -0.61 |
| Jasper Therapeutics, Inc. (JSPR) | United States | $0.020B | -0.37 |
| Instil Bio, Inc. (TIL) | United States | $0.048B | -1.73 |
| Tevogen Inc. (TVGN) | United States | $0.049B | |
| BioCardia, Inc. (BCDA) | United States | $0.016B |